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Translational Relevance
Although early detection and conventional therapies have changed the natural history of breast cancer, many patients die from progressive disease. Dissection of the mechanisms underlying breast cancer progression may identify early markers for invasive tumors as well as specific targeted therapeutics, providing further improvement in the clinical outcomes of patients. This study recognizes a novel function for phosphodiesterase (PDE) type 5 in controlling malignant breast epithelial cell behavior, and provides important clinical implications that can impact the prediction of the risk, and the treatment of breast cancer patients. First, since enhanced PDE5 expression promotes the invasive potential of breast cancer cells and predicts a worse survival in patients, this enzyme may represent a valuable molecular candidate with prognostic significance. Moreover, being PDE5 a known druggable target, our findings may be promising for antitumor therapy with
Introduction
In 2012, an estimated 1,67 million new cases of invasive breast cancer were diagnosed among women and approximately 522,000 patients were expected to die from breast cancer world-wide (1) . Despite advances in surgery, radiation and therapy, metastatic disease represents the most important contributor to breast cancer-related mortality (2) . Thus, novel marker and therapeutic target exploration is critical to the early detection, metastasis prevention, and effective treatment of human breast cancers.
Phosphodiesterases (PDEs) are metallo-hydrolases which catalyze the breakdown of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) into their biologically inactive 5′-derivatives, thus modulating the amplitude and duration of their intracellular signalings. In most tissues, PDE5 is the predominant isoform responsible for cGMP hydrolysis and its activity is tightly controlled by cGMP itself (3) . cGMP regulates a myriad of biological processes, including cell growth and adhesion, energy homeostasis, neuronal signaling, and muscle relaxation (4, 5) . In addition, dysregulation of cGMP homeostasis was observed in various (patho)physiological conditions, including cancers. Indeed, cGMP signaling, through activation of downstream effectors (i.e., cGMP-dependent protein kinase G-PKG, cyclic-nucleotide-gated ion channels) and/or crosstalk with cAMP pathways, appears to play an important role in promoting apoptosis and inhibiting proliferation of certain epithelial cells (6, 7) . Interestingly, PKG expression or cGMP levels are reduced in cancer cells and tissues compared to their normal counterparts (8, 9) .
In the last ten years, overexpression of PDE5 has been described in multiple human carcinomas, including bladder, lung and breast cancers (10) (11) (12) (13) . The increased expression of PDE5 in human malignancies coupled with the efficacy and high tolerability profiles of PDE5 inhibitors (i.e. sildenafil and vardenafil) in the treatment of erectile dysfunction and pulmonary hypertension have led to an increased interest in investigating PDE5-targeted drugs in cancer management (14, 15) . Author Manuscript Published OnlineFirst on December 14, 2015; DOI: 10.1158/1078-0432.CCR- PDE5 inhibitors in cancer cell lines, as those of the breast (13, 14, 16, 17) . Another PDE5 inhibitor, the nonsteroidal anti-inflammatory drug exisulinid inhibited growth and induced apoptosis in human tumor cells through cGMP elevation and PKG activation (12, 18, 19) . PDE5 inhibitors also increased the efficacy of chemotherapy agents in cancer models (20) . Recently, it has been reported that modulation of host immune response represents an additional mechanism by which PDE5 inhibitors may block tumor progression (21) . However, despite these studies, neither the expression of PDE5 in breast cancer cell lines and tissues nor the underlying regulatory molecular mechanisms by which PDE5 expression may contribute to breast cancer progression have been deeply studied.
Being PDE5 a well-characterized druggable target, in this study we propose to examine PDE5's impact on breast cancer phenotype in vitro, as well as to assess its clinical relevance in breast cancer patients.
Materials and Methods

Reagents, antibodies and plasmids
Sildenafil/Y-27632 were from Sigma; PDE5A/p-c-Myc
Thr58/Ser62 /c-Myc/p-IκB-α Ser32/36 /IκB-α/NFkBp65/Laminb/GAPDH antibodies from Santa Cruz Biotechnology; RhoA-C/Cdc42/Rac1-3 from Life Technologies; Cofilin activation/Myosin Light Chain 2 antibody sampler kits from Cell
Signaling. pEGFP-C1 vector and the fusion protein expression vector pEGFP-PDE5A were provided by Dr F. Barbagallo (Sapienza-University, Rome-Italy). Scrambled and 4-unique 29mer
PDE5A shRNA constructs in pGFP-C-shLenti vector were from Origene.
Cell culture
MCF-7/T47D/ZR-75/SKBR3/BT-20 and MDA-MB-468/MDA-MB-435 breast cancer cell lines
were from American-Type-Culture-Collection and Interlab-Cell-Line-Collection, respectively, where they were authenticated, stored following suppliers and used within six-months after frozen- antibiotic (1mg/ml, Life Technologies), and positive clones were identified using fluorescence microscopy and immunoblot analysis. Cells were authenticated, every six-months (last examined in February 2015), by short-tandem-repeat profiling, morphology, doubling-times, and tested for mycoplasma-negativity (MycoAlert, Lonza).
Transient transfection
For overexpression studies, T47D cells were transfected with pEGFP-C1 or pEGFP-PDE5A vectors and for gene silencing, MDA-MB-468 cells with scrambled or PDE5A shRNA constructs using Fugene6. After 48h, cells were harvested and used in different experimental procedures.
RT-PCR assays
PDE5 and 36B4 gene expression were evaluated by reverse transcription (RT)-PCR method as described (22) . Primers: forward 5'-ACTTGCATTGCTGATTGCTG-3' and reverse 5'-TTGAATAGGCCAGGGTTTTG-3' (PDE5A); forward 5'-CAAATCCCATATCCTCGTCC-3' and reverse 5'-CTCAACATCTCCCCCTTCTC-3' (36B4).
Immunoblot analysis
Cell extracts were resolved by SDS-PAGE, as described (22) . Immunoblots show a single representative of three-separate experiments.
Fluorescence microscopy
Cells were fixed with 4% paraformaldehyde and permeabilized with PBS+0.2% TritonX-100. 
MTT cell proliferation assays
Three days after seeding, cell proliferation was assessed using 3-[4,5-Dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide reagent/MTT (Sigma) and expressed as fold change relative to empty vector-transfected cells. Data represent three-independent experiments, performed in triplicate.
Wound-healing assays
Cell monolayers were scraped and subjected to various experimental conditions. Wound closure was monitored over 24h, cells were fixed and stained with Comassie-Brillant-Blue. Pictures represent one of three-independent experiments (10X-magnification, phase-contrast microscopy).
Transmigration assays
Cells under the various experimental conditions were placed in upper compartments of Boydenchambers (8µm-membranes, Corning). Bottom well contained regular-growth media. After 24h, migrated cells were fixed and stained with DAPI. Migration was quantified by viewing fiveseparate fields/membrane (10X-magnification) and expressed as mean numbers of migrated cells.
Data represent three-independent experiments, assayed in triplicate.
Invasion assays
Matrigel-based invasion assay was performed in Boyden-chambers (8µm-membranes) coated with Matrigel (BD Bioscences, 0.4µg/ml), as described (23) . After 24h, invaded cells were quantified as reported for transmigration assays.
RNA library preparation and sequencing
Total RNA was extracted from vector-and PDE5-expressing cells and libraries were prepared and sequenced as described in Supplementary Materials and Methods.
Research. 
Rho GTPase activation assays
Rho GTPases activation was determined by active Rho and Cdc42 pull-down and detection kits, following manufacturers (Life Technologies).
Phalloidin staining
Polymerized actin stress fibers were stained with Alexa Fluor 568-conjugated phalloidin, following manufacturers (Life Technologies). Cell nuclei were counterstained with DAPI.
OLYMPUS-BX51 microscope (100X-magnification) was used for imaging.
Patients and tissue specimens
A total of 35 primary breast carcinomas and three non-neoplastic breast tissues were analyzed in this study. These carcinomas were obtained from patients who had undergone initial surgery and signed informed consent between 2012-2014 at Annunziata Hospital (Cosenza, Italy). The patients' age at diagnosis varied from 33 to 85 years (mean, 60.6 years; median, 57 years). Characteristics of the patient cohort are reported in Supplementary Table 1. Fresh tissues were formalinfixed/paraffin-embedded after surgical removal. Sections were stained with H&E to select samples consisting of at least 50% tumor cells and to establish the histologic type and grade (Supplementary Table 1 ). The clinical investigation conformed the Declaration of Helsinki of 1975 and was approved by ethics and institutional human subjects committees at Annunziata Hospital.
Classification of molecular subtypes
In breast cancer, immunohistochemistry has been used as a surrogate for molecular classification by gene expression profiling in large population-based studies, showing an acceptable level of accuracy for determining molecular phenotypes (24) (25) (26) . Breast subtype classification is described in Supplementary Materials and Methods. 
Immunohistochemical analysis
PDE5A expression in non-neoplastic and neoplastic breast tissues was detected as described in Supplementary Materials and Methods.
Database setup for retrospective study
The entire database contains 1988 patients (average overall survival: 8.07 years, ER-positive patients: 76%, lymphnode-positive patients: 47.3%). Illumina gene-chips published by the Metabric-consortia were downloaded from the EGA repository (27) . The raw gene-chip data were imported into R and summarized using beadarray package (28) . Quantile normalization was performed using preprocessCore package (29) .
Statistical analysis
Data were analyzed for statistical significance using two-tailed student's Test, GraphPad-Prism4.
Standard deviations/S.D. are shown. For RNA sequencing bioinformatics analysis, sequencing reads (50-60 million reads/sample on average) were trimmed, quality filtered and aligned, including junction-spanning reads back, to the human genome hg19 (Homo sapiens Ensembl GRCh37) using Tophat v.2.0.10 (30). HTSeq (31) was used to compute read counts across each gene, which were then used as input to R package DESeq2 (32) . DESeq2 was used to normalize read counts for library size and dispersion followed by tests for differential gene expression. Significant differentially expressed genes were determined using false discovery rate (FDR) cutoff ≤ 0.05 and at least 1.5-fold change between conditions. Functional analyses were performed with Ingenuity Pathway Analysis suit (Ingenuity Systems). For immunohistochemistry, the correlations between PDE5 and grading/ER/PR/HER2 status were examined with Mann-Whitney-U test, between PDE5 and breast cancer subtypes by Kruskal-Wallis test (GraphPad-Prism4). Kaplan-Meier survival plot, hazard ratio with 95% confidence intervals and logrank P value were calculated and plotted in R as These results may suggest that high PDE5 expression may be associated with more aggressive breast cancer phenotypes.
PDE5 overexpression affects motility and invasion of MCF-7 breast cancer cells.
In order to explore PDE5's role in breast cancer growth and progression, a breast tumor cell line that expresses the lowest levels of this enzyme, MCF-7, was chosen to generate breast cancer in vitro models exhibiting forced PDE5 overexpression. For direct visualization of PDE5 cellular location, the corresponding cDNA was cloned in frame with enhanced-green-fluorescent-protein (EGFP) in the mammalian expression vector pEGFP-C1 and stable clones were screened using (Fig. 1D) . We used these experimental models to first investigate whether PDE5 overexpression may cause any changes in cellular phenotypes, including proliferation, migration, and invasion. Anchorage-dependent growth assays revealed a slight, but significant increase in cell proliferation in all three PDE5 clones compared to vector-expressing cells (Fig. 1E) . We then evaluated the ability of PDE5 overexpression to influence cell migration in wound-healing scratch assays and found that PDE5-expressing cells moved the farthest in either direction to close the gap compared with vector-expressing cells (Fig. 1F) . Given the evident enhancement of motility in PDE5-overexpressing cells, the capacity of cells to migrate across uncoated membrane in transmigration assays or invade an artificial basement membrane Matrigel in invasion assays was tested. Although vector-expressing cells exhibited little motile and no invasive behavior in vitro, our data clearly showed that PDE5 overexpression significantly increased both motility and invasion of MCF-7 cells (Fig. 1G and H) .
To evaluate the effects of PDE5 inhibition on breast tumor cell migratory and invasive properties, cells were treated with the specific PDE5 inhibitor sildenafil ( Fig. 2A-C) . We found that sildenafil treatment was able to completely restore in PDE5 1/2/3 clones the less motile and weak invasive behavior similar to that of control MCF-7 e.v. cells. Interestingly, although at less extent, sildenafil caused a significant decrease in motility and invasion of vector-expressing cells (by 73% and 65%, respectively). This may suggest that PDE5 activity is required for controlling migration and invasion processes also of malignant breast epithelial cells expressing low levels of the enzyme.
Role of PDE5 in motility and invasion of T47D and MDA-MD-468 breast cancer cells.
To extend the results obtained, we transfected vector and PDE5-expression plasmids in T47D luminal A-like breast cancer cells (Fig. 3A) . As previously shown for MCF-7 cells, we found a significant increase in both migratory and invasive cell potential when PDE5 was overexpressed and treatment with the selective PDE5 inhibitor sildenafil completely abrogated these effects ( Fig.   3B and C) . Again, PDE5 inhibition was associated with a significant reduction of motility and invasion also in vector-expressing cells (Fig. 3B and C) . In addition, as a third confirmatory model we silenced PDE5 expression in MDA-MB-468 breast cancer cells, that express high levels of PDE5 compared to MCF-7 and T47D cells (Fig. 3D ). Motility and invasion were significantly reduced in PDE5sh-transfected cells compared to control shRNA-transfected cells ( Fig. 3E and F) .
Thus, PDE5 may be an important determinant of breast tumor cell motility and invasion.
PDE5-overexpressing cells exhibit increased Rho GTPase activation.
To gain insights into the biological properties of the highly migratory and invasive PDE5- Table 2 ). These genes were next subjected to Ingenuity Pathway Analysis (IPA) to rank enriched biological processes (Fig. 4A) , and to calculate the activation z-score of molecular and cellular functions and pathways ( Fig. 4B and C) . In line with our previous experiments, cellular movement was the most significantly overrepresented biological process in PDE5-expressing cells. In addition, many differentially-expressed genes were involved in cell death and survival, cell-to-cell signaling and interaction, cell growth and proliferation, cellular development, thus concurring to identify the five top enriched functional categories in PDE5 clones (Fig. 4A) . Interestingly, analyzing the functions involving differentially-expressed genes, migration of cells and cell movement resulted to be highly activated by PDE5 (Fig. 4B) . Then, considering the most affected pathways by PDE5 overexpression, we found marked changes in the activity of Rho GTPase family, with RhoA, Cdc42 and Rac signalings showing activation z-score of 1.9, 1.342, and 0.302, respectively (Fig. 4C) . The predicted activation of these canonical pathways was confirmed using molecule activity predictor analysis of IPA ( Fig. 4D and Supplementary Fig. 1 ). An enriched Rho GTPases signaling profile is consistent with the enhanced migration and invasion capabilities of PDE5-expressing cells, as these proteins are known to govern cell cytoskeleton organization, migration, and metastasis dissemination (38) .
To validate the gene expression profile identified by RNA sequencing, we compared expression and activation of Rho family of GTPases in vector and PDE5 clones. Increased protein levels of Rho A-C, Cdc42 and Rac 1-3 (Fig. 5A , input panel) along with increased levels of activated forms (Fig.   5A , GTP-bound panel) were detected in PDE5-overexpressing cells. In the GTP-bound form, these proteins are able to interact with effector molecules (i.e. mainly the Rho kinase ROCK and the p21-activated kinase PAK1) to induce phosphorylation of LIM Kinase (LIMK), which is able to inhibit (by phosphorylation) Cofilin, leading to stabilization of filamentous actin structures (39) . ROCK has also been shown to phosphorylate the regulatory Myosin Light Chain (MLC), which enhances its binding to F-actin (40) . Consistent with increased Rho GTPase activation, the levels of phosphorylated LIMK, Cofilin and MLC are greatly increased in PDE5 clones compared to e.v. cells ( Fig. 5B and C) . Among other downstream targets of Rho signaling, c-Myc and NF-κB are important for cell motility and invasion (39, 41, 42) . In PDE5-overespressing cells, we detected elevated levels of the activated form of c-Myc (phospho c-Myc), whereas we did not observe NF-κB activation, as evidenced by no changes in phosphorylation of the inhibitor of NF-κB IκBα as well as in NF-κB nuclear translocation (Supplementary Fig. 2 ). To further investigate the role of Rho GTPases activation on cytoskeletal organization in our model systems, we evaluated the formation of stress fibers, since they provide the contractile force required for motility (Fig. 5D) . In the selective ROCK inhibitor Y-27632 was able to significantly reduce both migration and invasion of PDE5 clones ( Fig. 5E and F) . Collectively, our data strongly suggest that the molecular and cellular functions identified with IPA are biologically relevant and PDE5 may regulate motility and invasion through activation of the Rho family of GTPases.
PDE5 expression in human breast cancers.
To evaluate the clinical significance of PDE5 in human breast tumors, we analyzed its expression levels in patient-derived tissues (n=35) by immunohistochemistry analysis. The characteristics of all patients are listed in Supplementary Table 1 . We found that ~85% of cases showed cytoplasmic staining for PDE5 in cancer cells. Interestingly, ER/PR-positive tumors exhibited weak (n=5) or intermediate (n=15) PDE5 staining, while the strongest staining intensity was observed among HER2-positive or triple negative (TN) samples (n=15). In contrast, in nonneoplastic (NN) breast tissues (n=3), a weak to missing PDE5 expression was detected in the cytoplasm. Representative images of PDE5 staining patterns are shown in Figure 6A . Accordingly, PDE5 expression had a significant inverse correlation with ER and PR status ( Fig. 6B and C) and a significant positive correlation with HER2 status (Fig. 6D) . Of note, as the staining intensity of PDE5 increases, grading of cancer cells also tended to increase (p = 0.001), indicating that the higher expression of PDE5 might be related with a higher malignancy phenotype.
We then correlated PDE5 expression with the different subtypes of breast carcinoma and found that its cytoplasmic expression was significantly different among the four molecular subtypes (Fig.   6E ). In particular, in HER2 and triple-negative subtypes, PDE5 expression was the highest, immunohistochemically may have lower PDE5 levels compared to ER-negative ones. In line with findings on patients, PDE5 expression also varies among different breast cancer cell line models.
Taken together, our results suggest that the differential expression of PDE5 may contribute to breast cancer heterogeneity and, being PDE5 a known druggable target, it could help to integrate subsets of aggressive breast cancer into clinically meaningful subtypes.
At the present time, the selective PDE5 inhibitors sildenafil (Viagra and Revatio-Pfizer) and tadalafil (Cialis-Eli Lilly; Adcirca-United Therapeutics) have Food and Drug Administration approval for the treatment of erectile dysfunction (ED) as well as pulmonary artery hypertension; whereas vardenafil (Levitra and Vivanza-Bayer) and avanafil (Stendra-Vivus) are approved only for ED. However, due to their favorable toxicity profile (44), these agents are being investigated in a wide range of other potential medical and surgical applications, including neurological and cardiovascular disorders, transplant and reconstructive surgery, and several clinical trials are currently in progress (15) . In the last ten years, various PDE5 inhibitors have been also reported to inhibit growth and induce apoptosis in many cancer cell lines, without affecting normal epithelial cells (12-14, 16, 18, 19) . Recently, two reports have suggested a role for PDE5 inhibition in influencing cancer cell motility (17, 45) . Indeed, tadalafil and sildenafil reduced the capacity of thyroid cancer cells to migrate at lower doses than those used to block proliferation (17) . Similarly, down-regulation of PDE5 in the aggressive human breast cancer cell line MDA-MB-231T resulted in no difference in cell proliferation and reduced motility in vitro and in vivo (45) . Here, we show In conclusion, results of this study highlight a novel role for PDE5 in controlling malignant breast epithelial cell behavior and provide the first indications for the clinical relevance of this enzyme in human breast cancers. Since PDE5 overexpression greatly enhances the invasive potential of breast cancer cells and reduces survival in patients, it is tempting to speculate that this enzyme may represent a novel prognostic biomarker candidate. In addition, having already addressed the delivery, stability and toxicity issues of PDE5 inhibitors in other diseases, our findings may offer promising insights into future cancer treatments by providing the rationale to implement safer and more efficacious drugs in the adjuvant therapy for improving clinical care and reducing mortality from breast cancer. This may assume particular significance in triple-negative breast cancers in which PDE5 may be an attractive target. Based on these observations, it is evident that the impact of PDE5 in the prediction of the risk, and the treatment of breast cancer patients deserves further attention. 
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